Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: Understanding Current First-line Strategies

FACULTY

Jacob Sands, MD
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, MA

Sarah Tangerini, NP
Thoracic Oncology Program
Dana Farber Cancer Institute
Boston, MA

Ajay Sheshadri, MD, MSCI
Associate Professor, Pulmonary Medicine
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

PROGRAM OVERVIEW

This activity provides a practice-based learning experience for medical oncologists, pulmonologists, nurse practitioners, and other health care providers, regarding the assessment and treatment of non-small cell lung cancer (NSCLC) in the first-line setting. By participating in this Simulation Center, learners will observe an interaction between a patient with NSCLC and their healthcare provider, and will test their knowledge of diagnosis and management at key decision points along the way.

TARGET AUDIENCE

This activity is designed to meet the educational needs of medical oncologists, oncology nurses, pulmonologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies.

LEARNING OBJECTIVES

• Evaluate the immune processes integral to the pathogenesis of NSCLC and strategies for immunotherapeutic management
• Incorporate clinical trial data on the latest checkpoint inhibitors into the management of NSCLC, including PD-1 and PD-L1 inhibitors
• Interpret biomarker data for selection of first-line checkpoint inhibition in advanced NSCLC and identify potential adverse events associated with checkpoint inhibitors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT INFORMATION

Purpose: Education regarding the first-line management of advanced non-small cell lung cancer, including current and emerging treatments, leads to safe practice, quality care, and continuous professional and personal development for oncology nurses.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Ajay Sheshadri, MD, MSCI

• Consulting fees within the last 36 months: Enanta Pharmaceuticals, PsiOxus Therapeutics
• Funding to institution: National Institutes of Health, Gateway for Cancer Research Foundation

Sarah Tangerini, NP

• Nothing to disclose.

Jacob Sands, MD

• Consultant: AstraZeneca, Jazz Pharmaceuticals, Medtronic

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

• Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
• Angela Davis, PhD, Medical Director of Med Learning Group, has nothing to disclose.
• Melissa Johnson, Senior Program Manager of Med Learning Group, has nothing to disclose.
• Amanda Jenkins, Associate Program Manager of Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
• Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
• Aimee Meissner, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this online activity. To receive CME/CE credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]